Receive our newsletter – data, insights and analysis delivered to you
July 7, 2009

FDA Accepts Once-Weekly Exenatide for Review

The US Food and Drug Administration has accepted for review a New Drug Application (NDA) for the once-weekly diabetes drug exenatide produced by Amylin Pharmaceuticals, Eli Lilly and Alkermes. Exenatide is an investigational sustained release medication for type 2 diabetes that is adminis

By cms admin

The US Food and Drug Administration has accepted for review a New Drug Application (NDA) for the once-weekly diabetes drug exenatide produced by Amylin Pharmaceuticals, Eli Lilly and Alkermes.

Exenatide is an investigational sustained release medication for type 2 diabetes that is administered once a week subcutaneously by injection.

Exenatide is the active ingredient in Byetta (exenatide) injection, which is available in the US and other countries for people with type 2 diabetes who are unable to achieve good glycaemic control with common oral therapies.

Amylin Pharmaceuticals senior vice-president of research and development Orville G Kolterman said that the acceptance of the NDA submission for exenatide once weekly is an important milestone in the exenatide development programme and in the treatment of type 2 diabetes.

“If approved, this therapy could fill an important unmet need for treating patients with type 2 diabetes with just one dose per week,” Kolterman said.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU